Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 15/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27608171 | 0.85 | GOT1 (0.63) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL18690982 | 0.83 | GAA (0.66) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL28720422 | 0.83 | GOT1 (1.00) | GOT1GAAMAPTRECQL | |
| SCHEMBL13933664 | 0.81 | GAA (0.74) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL1537795 | 0.81 | GAA (0.60) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL30885791 | 0.81 | GAA (0.60) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL13933666 | 0.80 | GAA (0.78) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL2354773 | 0.80 | GOT1 (0.60) | GOT1GAAMAPTRECQLDRD2 | |
| SCHEMBL1570271 | 0.80 | ADRB1 (0.58) | GOT1GAAMAPTRECQLADRB1 | |
| SCHEMBL7781598 | 0.79 | ADRB1 (0.61) | GOT1GAAMAPTRECQLADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| WO-2011088836-A1 | NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS | H. LUNDBECK A/S (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011088838-A1 | NOVEL 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACEPHENANTHRYLENE DERIVATIVES AS DOPAMINE D2 LIGANDS | H. LUNDBECK A/S (DK) | 2011-07-28 | — | — | WO | disclosed |
| CN-101730680-A | Has 5-HT 64 ' the compound that replaces of receptor affinity | MEMORY PHARM CORP | 2010-06-09 | — | — | CN | disclosed |
| EP-2162433-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| CN-101456780-A | Deprotection of n-boc compounds | HOFFMANN LA ROCHE (CH) | 2009-06-17 | — | — | CN | disclosed |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008147812-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-04 | — | — | WO | disclosed |
| CN-1871236-A | Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders | BIOVITRUM AB (SE) | 2006-11-29 | — | — | CN | disclosed |
| CN-1222511-C | I-aryl-or-I-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-b ligands | WYETH CO (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1484638-A | I-aryl-or-I-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-b ligands | — | 2004-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | GOT1 4362/4885GAA 4365/4885MAPT 3625/4885 |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR3B | GOT1 3940/4885GAA 3831/4885MAPT 4412/4885 |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | GOT1 3167/4885GAA 3260/4885MAPT 1420/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | GOT1 1252/4885GAA 1690/4885MAPT 4002/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | GOT1 3820/4885GAA 4190/4885MAPT 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.